← Compound index
COMPOUND RECORD / STEMOKIN

Stemokin / NeogenСтемокин / Неоген

A synthetic three-amino-acid peptide (Ile–Glu–Trp), also called Neogen, studied in blood-cell and immune research.

Source linked

What the studies found

Comparison in people · 2015

Stemokin in treatment and prevention of pyoderma in military personnel

Reported clinical recovery in the adjunct-treatment arm
74.36% among 39 treated participants
Reported pyoderma incidence in the prevention arm
17.5% among 40 participants over follow-up up to 12 months

The report compares adjunctive treatment in groups of 39 and 37, and prevention in groups of 40 and 36. Reported recovery was 74.36% versus 21.62%; reported infection incidence was 17.5% versus 58.3% during follow-up up to 12 months. Allocation and blinding are unclear. The 2011 dissertation appears to report overlapping groups; neither publications nor the two investigations establish 152 unique participants.

Study notes · methods, sources and limitations

Participants or model Treatment comparison: 39 adjunctive Stemokin versus 37 basic care; prevention comparison: 40 versus 36. Participant overlap unresolved.

Important limitations

  • Independent replication and full risk-of-bias appraisal remain unresolved. No personalized treatment or safety conclusion follows from this record.
  • These arm-level proportions are not causal effect estimates. The excerpt gives no percentages for the comparison group. Allocation, blinding and overlap between the treatment and prevention groups remain unresolved; the reports may count some participants more than once.

Conference abstract on Dermatology in Russia, posted 25 January 2015; underlying study dates unresolved · Conference abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2016

Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.

Study of multiple preparations

Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.

Study notes · methods, sources and limitations

Participants or model Intact mice, donor marrow and irradiated recipient-mouse colony assays

Important limitations

  • AWE18 is a later development label; do not generalize the activity of other numbered analogues to it. No human trial is reported. Related publications may share experiments; source count is not independent-study count.

ChemMedChem · Publication record

Original source or citation ↗

Study results and tables ↗

Animal research · 2005

Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.

Study of multiple preparations

Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.

Study notes · methods, sources and limitations

Participants or model Mice; splenic colony-forming, CD34-positive-cell and T-cell assays

Important limitations

  • Mechanistic interpretation does not establish CD34 as a directly bound receptor. Related-isomer experiments do not prove clinical effects of either marketed preparation. Colony formation is not proof of long-term self-renewing stem-cell expansion.

Bulletin of Experimental Biology and Medicine. 140(3):348–351 · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Stemokin / Neogen

Names in this research collection

Neogen · IEW

Research background

Synthetic Ile–Glu–Trp tripeptide (IEW), studied in hematopoietic experiments and Russian clinical immune research. It is distinct from whole tissue extracts.

Autoimmune research: disease-specific findings, immune effects and open questions ↗

Conference sources and research collaborators ↗

Compound class
Peptide / preparation research
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Comparative clinical report; methods and overlap unresolved

Study methods

Source-specific designs and limitations below

Independent replication

Related reports are not automatically independent evidence

Source access

Linked publications; access and review scope shown per record

Safety evidence

Clinical safety, product equivalence and interactions not established by this collection

Open a topic for the evidence assessment.

More findings, background and history
RELATED PEPTIDE RESEARCH / UPDATED OCTOBER 2026

Connections in the research

The MP family provides a separate marrow-regulation research comparison; it does not share Stemokin’s preparation-specific evidence.

View the peptide family map and sources ↗

What remains unclear

Group assignment, comparators, planned outcomes, effect estimates, adverse events and possible participant overlap are key limits to interpreting the studies.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2000 · US6159940A · Stemokin / Neogen: Ile-Glu-Trp and hematopoiesisUse · Lifetime reported approximately 4 days longer after peptide-related tumor-cell treatment and 15 days longer in a combination experiment

Reported findings

Some animal survival and immune-cell observations were favorable, without an established human treatment result.

Tumor-model survival descriptions
Lifetime reported approximately 4 days longer after peptide-related tumor-cell treatment and 15 days longer in a combination experimentDifferent experimental conditions; not patient survival
Longer combination observation
An approximately 20-day survival extension and survivors at 60 days described for another combinationThe effect reflects the combination. The contribution of Ile-Glu-Trp alone is unclear.
All reported results, comparisons and limitations →

Use. The claimed peptide class includes Ile-Glu-Trp explicitly in a method directed at hematopoiesis.

The family contains multiple sequences; a peptide use claim is not proof of broad clinical immune restoration.

Publication
US6159940A ↗ · 2000-12-12
Earliest priority / filing
1996-02-28 / 1999-06-28
Original applicant / assignee
Immunotech Developments Inc
Indexed status
Expired - Lifetime · checked 2026-11-06
Patent family
26653668 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method for modulating hemopoiesis

Inventors: Vladislav I. Deigin; Andrei M. Korotkov.

US6159940A

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2000

Stemokin / Neogen: Ile-Glu-Trp and hematopoiesis — US6159940A

Some animal survival and immune-cell observations were favorable, without an established human treatment result.

Tumor-model survival descriptions · Lifetime reported approximately 4 days longer after peptide-related tumor-cell treatment and 15 days longer in a combination experiment · Different experimental conditions; not patient survival

Study notes and original source
2000Patent / reported experimentsFull text available

Stemokin / Neogen: Ile-Glu-Trp and hematopoiesis — US6159940A

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Vladislav I. Deigin, Andrei M. Korotkov · US6159940A · patent family 26653668

Some animal survival and immune-cell observations were favorable, without an established human treatment result.

Results and tables

Reported patent results

Reported findings

Some animal survival and immune-cell observations were favorable, without an established human treatment result.

Ile-Glu-Trp/Stemokin preclinical hematopoiesis, immune and tumor-model experiments; the description recommends subsequent clinical testing.

Population or model Ile-Glu-Trp/Stemokin preclinical hematopoiesis, immune and tumor-model experiments; the description recommends subsequent clinical testing.

Results · Description: tumor-model narrative and general toxicity/cell-count observations.
MeasureResultComparison, timing and statistics
Tumor-model survival descriptionsLifetime reported approximately 4 days longer after peptide-related tumor-cell treatment and 15 days longer in a combination experimentDifferent experimental conditions; not patient survival
Longer combination observationAn approximately 20-day survival extension and survivors at 60 days described for another combinationThe effect reflects the combination. The contribution of Ile-Glu-Trp alone is unclear.
Animal observationsNo deaths reported during the described 30-day toxicity observation; selected thymus/spleen cell counts increasedThese observations do not establish a human safety margin · 30 days

Different animal protocols and combinations cannot be pooled. No reliable human immune-restoration or cancer-treatment effect is established by this disclosure.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Ile-Glu-Trp/Stemokin preclinical hematopoiesis, immune and tumor-model experiments; the description recommends subsequent clinical testing.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The family contains multiple sequences; a peptide use claim is not proof of broad clinical immune restoration.
  • Different animal protocols and combinations cannot be pooled. No reliable human immune-restoration or cancer-treatment effect is established by this disclosure.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2005

Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.

Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.

Study notes and original source
2005Animal / experimentalEnglish abstract

Effects of iEW synthetic peptide isomers on bone marrow colony-forming capacity in vivo.

Related L- and D-iEW isomers; preparation equivalence is not inferred

Format: Journal article · Reviewed: Indexed abstract reviewed

O. V. Semina, T. N. Semenets, I. A. Zamulaeva, E. I. Selivanova, Ya. V. Malyutina, Yu. A. Semin, V. I. Deigin, A. S. Saenko · Bulletin of Experimental Biology and Medicine. 140(3):348–351

Experiments with peptide isomers and neuraminidase linked differing colony-forming responses to the T-cell microenvironment. The authors proposed shared CD34-associated surface interactions.

Population / setting
Mice; splenic colony-forming, CD34-positive-cell and T-cell assays
Source reviewed
Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
  • Mechanistic interpretation does not establish CD34 as a directly bound receptor.
  • Related-isomer experiments do not prove clinical effects of either marketed preparation.
  • Colony formation is not proof of long-term self-renewing stem-cell expansion.

Reviewed 2026-10-03.

Read the source ↗

Animal research · 2016

Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.

Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.

Study notes and original source
2016Animal / experimentalFull text available

Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.

Preparation-specific research; no equivalence inferred

Deigin V, Ksenofontova O, Khrushchev A, Yatskin O, Goryacheva A, Ivanov V. · ChemMedChem

Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.

Population / setting
Intact mice, donor marrow and irradiated recipient-mouse colony assays
Source reviewed
Full primary text checked: compound 3 is the alanine cyclic scaffold later discussed as AWE18 in the 2023 platform review. Experimental comparisons concern mice and irradiated marrow; supporting raw data not independently reanalyzed.
Study limitations
  • AWE18 is a later development label; do not generalize the activity of other numbered analogues to it. No human trial is reported.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2003

[Immunogenic peptide neogen stimulates postradiation recovery thrombopoiesis].

Neogen was investigated for platelet and bleeding-time recovery after irradiation in mice. Animal recovery endpoints do not establish clinical hematologic benefit.

Study notes and original source
2003Animal / experimentalEnglish abstract

[Immunogenic peptide neogen stimulates postradiation recovery thrombopoiesis].

Preparation-specific research; no equivalence inferred

Ziablitskiĭ VM, Semina OV, Semenets TN, Starosel'skaia AN, Romanovskaia VN, Mikhal'skaia TIu, Poverennyĭ AM, Deĭgin VI. · Radiatsionnaia biologiia, radioecologiia

Neogen was investigated for platelet and bleeding-time recovery after irradiation in mice. Animal recovery endpoints do not establish clinical hematologic benefit.

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Animal research · 2024

Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation

Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.

Study notes and original source
2024Animal / experimentalFull text available

Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation

Defined synthetic peptide / analogue

Vladislav Deigin, Yulia Vinogradova, Dmitriy Vinogradov, Natalia Linkova, Anastasiia Dyatlova, Dmitrii Medvedev, Alexander Krasichkov, Victoria Polyakova · International Journal of Molecular Sciences 25(24):13385

Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.

Results and tables

Reported findings and study design

Population or model Source-specific experimental population

Results · Original full-text XML; Table 1 and reporting limitations in Tables 2–3
MeasureResultComparison, timing and statistics
Intact-mouse spleen colony formationControl 14.5±1.6 colonies per 100,000 cells; CP-88 injected 19.9±1.3, oral 19.3±1.3; both marked p<0.05 versus control.
Stemokin in the same table14.7±0.7 injected and 14.3±1.8 oral; neither carries a significance mark.

No CP-88-versus-Stemokin significance is established by separate control tests. Table 2 footnotes and Table 3 marker/header labels need clarification. Colony formation does not establish long-term stem-cell self-renewal or human benefit.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Source-specific experimental population
Source reviewed
Original full text retrieved from Europe PMC; experimental scope and interpretation checked. Supplementary methods and independent replication remain review targets.
Study limitations
  • Independent replication and full risk-of-bias appraisal remain unresolved.
  • No personalized treatment or safety conclusion follows from this record.

Reviewed 2026-11-06.

Read the source ↗

Review of earlier studies · 2023

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.

Study notes and original source
2023ReviewFull text available

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

Defined synthetic peptide / analogue

Vladislav Deigin, Natalia Linkova, Olga Volpina · International Journal of Molecular Sciences 24(17):13534

Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.

Population / setting
Source-specific experimental population
Source reviewed
Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Study limitations
  • Independent replication and full risk-of-bias appraisal remain unresolved.
  • No personalized treatment or safety conclusion follows from this record.

Reviewed 2026-10-02.

Read the source ↗

Comparison in people · 2015

Stemokin in treatment and prevention of pyoderma in military personnel

The report compares adjunctive treatment in groups of 39 and 37, and prevention in groups of 40 and 36. Reported recovery was 74.36% versus 21.62%; reported infection incidence was 17.5% versus 58.3% during follow-up up to 12 months. Allocation and blinding are unclear. The 2011 dissertation appears to report overlapping groups; neither publications nor the two investigations establish 152 unique participants.

Study notes and original source
2015Human comparative studyRussian-language source

Stemokin in treatment and prevention of pyoderma in military personnel

Defined synthetic peptide / analogue · Conference abstract

V. V. Gladko, N. N. Kakhishvili, S. A. Masyukova · Conference abstract on Dermatology in Russia, posted 25 January 2015; underlying study dates unresolved

The report compares adjunctive treatment in groups of 39 and 37, and prevention in groups of 40 and 36. Reported recovery was 74.36% versus 21.62%; reported infection incidence was 17.5% versus 58.3% during follow-up up to 12 months. Allocation and blinding are unclear. The 2011 dissertation appears to report overlapping groups; neither publications nor the two investigations establish 152 unique participants.

Results and tables

Reported findings and study design

Population or model Treatment comparison: 39 adjunctive Stemokin versus 37 basic care; prevention comparison: 40 versus 36. Participant overlap unresolved.

Results · Results from an indexed excerpt of the original conference abstract. The full abstract was unavailable from the host.
MeasureResultComparison, timing and statistics
Reported clinical recovery in the adjunct-treatment arm74.36% among 39 treated participants
Reported pyoderma incidence in the prevention arm17.5% among 40 participants over follow-up up to 12 months

These arm-level proportions are not causal effect estimates. The excerpt gives no percentages for the comparison group. Allocation, blinding and overlap between the treatment and prevention groups remain unresolved; the reports may count some participants more than once.

Source for these results ↗ · Reviewed 2026-11-05

Population / setting
Treatment comparison: 39 adjunctive Stemokin versus 37 basic care; prevention comparison: 40 versus 36. Participant overlap unresolved.
Source reviewed
Indexed original abstract passages rechecked; direct host access returned 403. Reported active-arm recovery and prevention proportions recovered; full dissertation appraisal pending.
Study limitations
  • Independent replication and full risk-of-bias appraisal remain unresolved.
  • No personalized treatment or safety conclusion follows from this record.

Reviewed 2026-11-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗